Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic

Size: px
Start display at page:

Download "Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic"

Transcription

1 Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications Andres A. Roma, MD Cleveland Clinic

2 No Disclosures In the past 12 months, I have not had a significant financial interest or other relationship with the manufacturer(s) of the product(s) or provider(s) of the service(s) that will be discussed in my presentation

3 Advances in Endocervical Adenocarcinoma Andres A Roma, M.D.

4 Endocervical adenocarcinoma New proposal for staging EAC based on tumor pattern rather than depth of invasion

5 Endocervical adenocarcinoma Current FIGO/AJCC stage on EAC Difficulties of determining early stages (based on pathologic/microscopic features) Treatment options based on stage and complications New proposal to address difficulties

6 FIGO/AJCC Staging of Cervical Carcinoma

7 Endocervical adenocarcinoma Most of staging based on squamous lesions of the cervix Management and natural history of the glandular counterpart of cervical carcinoma is less defined Treatment based on stage

8

9

10 Endocervical adenocarcinoma (clinical issues) Reports on safety of conservative management of stage I glandular lesions Controversy use of less radical treatments Lack in understanding of the natural history, lack of prospective, long-term follow-up for conservatively managed patients

11 Endocervical adenocarcinoma (pathology issues) Early stage based on pathologic (microscopic) features depth of stromal invasion Crucial pathologic prognostic parameter difficult to measure accurately or consistently Vascular invasion does not affect staging

12 Endocervical adenocarcinoma (pathology issues) 3 mm key depth invasion to avoid radical surgery and LN dissection

13

14

15

16

17

18

19 Difficulties of early stage EAC Smooth-contoured glands with cribriform or intrapapillary growth patterns mimicking AIS

20

21 Difficulties of early stage EAC Budding glands adjacent/associated with AIS Lack of desmoplastic stroma reaction

22

23 Does it matter to have accurate depth? 33 cases cone/leep of EAC stage IA Cases Depth LVSI Treatment LND Recurrence 21 3mm or less (IA1) 0/21 Conization 3 Hysterectomy 4 H + PLND 14 0/ more 3mm (IA2) 1/12 H + PLND 12 0/12 0 Poynor EA, et al. Gynecologic oncology 2006

24 Stage IA EAC literature review Lymph node metastasis IA1 2/228 (0.9%) IA2 3/179 (1.7%) Recurrence IA1 4/330 (0.9%) IA2 7/346 (2%) Poynor EA, et al. Gynecologic oncology 2006

25 Radical surgery and lymph node dissection complications Lymphedema incidence 1.6 to 41% Loss of childbearing Bladder/sexual dysfunction Halaska MJ et al. Int J Gyn Cancer 2010

26 Radical surgery and lymph node dissection complications 84% radical surgery with LN dissection No LVSI, margins negative in cone No LN metastasis Ceballos K, Onuma K, Hauspy J, et al. Early invasive cervical adenocarcinoma: is radical treatment indicated? USCAP 2012 Abstract #1102

27 Radical surgery and lymph node dissection complications 46% complications 16 (76%) cases bladder/sexual dysfunction 5 cases (24%) lymphedema 1 case severe neuropathy Vs 1 case infection post-conization Ceballos K, Onuma K, Hauspy J, et al. Early invasive cervical adenocarcinoma: is radical treatment indicated? USCAP 2012 Abstract #1102

28

29

30 Summary Endocervical adenocarcinoma Difficulties of determining early stages (based on pathologic/microscopic features) Treatment options based on stage, not necessarily followed or more radical option is elected

31 Summary Endocervical adenocarcinoma Lymph node dissections (LND) majority of pts Over 95% of LND are negative for metastasis Significant morbidity without obvious clinical benefit Many cervical cancer patients are young

32 The Problem The surgical treatment of EAC has been based on the depth of invasion knowing that it is not possible to do this accurately. Most patients will receive LN dissection trying to detect all cases of LN mets independent of true incidence.

33 Question Are there other pathologic parameters that better identify patients at risk of developing lymph nodes metastases?

34 Background Two previous studies from MD Anderson and Cedars-Sinai Medical Center Tumors evaluated based on pattern of invasion rather than depth of invasion Pattern of invasion was a good prognostic indicator *Aguilera-Barrantes I, Silva EG. Prognostic factors of adenocarcinoma of the endocervix: pattern of invasion vs depth of invasion. Mod Pathol. Volume 23 Feb 2010 Page 232A *Arville B, Silva EG, Galliano G, et al. Invasive endocervical adenocarcinoma: combining depth and pattern of invasion for better identification of patients with lymph node metastases. Mod Pathol. Volume 24 Feb 2011 Page 236A

35 Hypothesis Endocervical adenocarcinoma categorized by morphologic pattern of invasion rather than traditional depth of invasion better predicts for lymph node metastasis in patients with endocervical adenocarcinoma

36 Silva method Pattern A Well-demarcated glands with round contours, frequently forming groups Well to moderately differentiated morphology No cell detachment or obvious desmoplastic stromal invasion No lymphvascular space invasion Glands may have complex intraglandular growth (cribriform, papillae) Depth of tumor or relation to large vessels not relevant Pattern B Early stromal invasion arising from well-demarcated glands Pattern C Diffuse destructive stromal invasion (one 4x field) Severe cytologic atypia or poorly differentiated morphology

37 Pattern A

38

39

40

41

42 Silva method Pattern A Well-demarcated glands with round contours, frequently forming groups Well to moderately differentiated morphology No cell detachment or obvious desmoplastic stromal invasion No lymphvascular space invasion Glands may have complex intraglandular growth (cribriform, papillae) Depth of tumor or relation to large vessels not relevant Pattern B Early stromal invasion arising from well-demarcated glands

43 Pattern B

44

45

46

47

48

49

50

51

52

53 Silva method Pattern A Well-demarcated glands with round contours, frequently forming groups Well to moderately differentiated morphology No cell detachment or obvious desmoplastic stromal invasion No lymphvascular space invasion Glands may have complex intraglandular growth (cribriform, papillae) Depth of tumor or relation to large vessels not relevant Pattern B Early stromal invasion arising from well-demarcated glands Pattern C Diffuse destructive stromal invasion (one 4x field) Severe cytologic atypia or poorly differentiated morphology

54 Pattern C

55

56

57

58

59 Design Large multi-institutional study (12 institutions) Dx of Invasive Endocervical Adenocarcinoma (usual type only, no variants) Only resected cases (hysterectomy/trachelectomy/cone) with lymph node sampling

60 Design Pathologic parameters assessed: Depth of tumor Tumor size Tumor grade Lymphovascular invasion Pattern of tumor invasion (new system) LN metastasis Follow-up

61 Results Patients Pts with pos LN Total LN # Pos LN Stage I Stage II-IV Standard (14%) (1%) 324 (92%) 28 (8%) A 73 (20.7%) (100%) 0 B 90 (25.6%) 4 (4.4%) (0.2%) 90 (100%) 0 C 189 (53.7%) 45 (24%) (1.7%) 157 (83%) 32 (17%) LN metastases p< comparing Pattern A to B/C p= comparing Pattern A to B p< comparing Pattern A to C 21% of patient spared lymphadenectomy

62 Stage distribution by pattern Stage Pattern A Pattern B Pattern C IA S IA2 T A G E IA NOS IB IB I IB NOS II III IV Total Stage I vs. Stage II or higher p=0.002 comparing Pattern A to B/C p=0.5 comparing Pattern A to B p< comparing Pattern A to C

63 Results All cases (n=352) Tumor Depth <=3mm (86) >3-5mm (85) >5mm (180) >=10mm (99) LN Pos (49) 3 (3.4%) 6 (7%) 40 (22%) 32 (32%) Early stage IA1-IB1 (n=302) Tumor Depth <=3mm (83) >3-5mm (80) >5mm (139) LN Pos (24) 3 (3.6%) 5 (6.25%) 16 (11.5%) 2 Pattern B IB1 LVI+ 2 Pattern B IA2; IB1 LVI+ 1 Pattern B IB1 LVI+ 1 Pattern C IA1 LVI+ 3 Pattern C IB1 LVI+ 15 Pattern C IB1 LVI+

64 IMPORTANT!!! NOTE: Must be certain that entire tumor was evaluated histologically before diagnosing pattern A.

65 First do a biopsy; if pattern C then radical hysterectomy + PLND If pattern A; then conization (entirely submitted) If pattern A persists in the cone with negative margins and no LVI, stop and follow-up (deeper sections might be necessary to exclude LVI) If pattern B; radical hysterectomy and sentinel LN If LN is positive then PLND

66 Conclusions Staging endocervical adenocarcinoma by pattern of invasion rather than depth of invasion would have identified 21% of patients who did not need LND (Pattern A) Pattern B rarely has lymph node mets (sentinel LN might detect cases with positive LNs and avoid unnecessary complications) Aggressive treatment for patients with pattern C

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells 2013 California Society of Pathologists 66 th Annual Meeting San Francisco, CA Atypical Glandular Cells to Early Invasive Adenocarcinoma: Cervical Cytology and Histology Christina S. Kong, MD Associate

More information

SLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA

SLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA Lead Grou p Log SLN Mapping in Cervical Cancer Nadeem R. Abu-Rustum, M.D. Memorial Sloan Kettering Cancer Center New York, USA Conflict of Interest Disclosure Nadeem R. Abu-Rustum, M.D. I have no financial

More information

Currently, the parameters that determine stage and

Currently, the parameters that determine stage and ORIGINAL ARTICLE Invasive Endocervical Adenocarcinoma A New Pattern-based Classification System With Important Clinical Significance Andres A. Roma, MD,* Andrea Diaz De Vivar, MD,w Kay J. Park, MD,z Isabel

More information

In situ and Invasive Endocervical Carcinoma: Problems and Pitfalls in Diagnosis

In situ and Invasive Endocervical Carcinoma: Problems and Pitfalls in Diagnosis In situ and Invasive Endocervical Carcinoma: Problems and Pitfalls in Diagnosis Rouba Ali-Fehmi,MD The Karmanos Cancer Institute, Wayne State University School of Medicine Global incidence of cervical

More information

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive

More information

CPC on Cervical Pathology

CPC on Cervical Pathology CPC on Cervical Pathology Dr. W.K. Ng Senior Medical Officer Department of Clinical Pathology Pamela Youde Nethersole Eastern Hospital Cervical Smear: High Grade SIL (CIN III) Cervical Smear: High Grade

More information

ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data

ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data David Cibula Gynecologic Oncology Centre General University Hospital

More information

Factors Predicting Pelvic Lymph Node Metastasis, Relapse, and Disease Outcome in Pattern C Endocervical Adenocarcinomas

Factors Predicting Pelvic Lymph Node Metastasis, Relapse, and Disease Outcome in Pattern C Endocervical Adenocarcinomas International Journal of Gynecological Pathology 00:1 10, Lippincott Williams & Wilkins, Baltimore r 2017 International Society of Gynecological Pathologists Original Article Factors Predicting Pelvic

More information

Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer

Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer 대한부인종양콜포스코피학회제 24 차학술대회 Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer Seoul National University Bundang Hospital Eun Jung Soh, M.D. Cervical cancer

More information

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?

More information

ECC or Margins Positive?

ECC or Margins Positive? CLINICAL PRESENTATION This practice algorithm has been specifically developed for M. D. Anderson using a multidisciplinary approach and taking into consideration circumstances particular to M. D. Anderson,

More information

Gynecologic Cancer InterGroup Cervix Cancer Research Network. The SHAPE Trial

Gynecologic Cancer InterGroup Cervix Cancer Research Network. The SHAPE Trial Gynecologic Cancer InterGroup Cervix Cancer Research Network The SHAPE Trial Comparing radical hysterectomy and pelvic node dissection against simple hysterectomy and pelvic node dissection in patients

More information

Staging and Treatment Update for Gynecologic Malignancies

Staging and Treatment Update for Gynecologic Malignancies Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding Cervical Cancer Abnormal vaginal bleeding Postcoital, intermenstrual or postmenopausal Vaginal discharge Pelvic pain or pressure Asymptomatic In most patients who are not sexually active due to symptoms

More information

Invasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous

Invasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous Note: If available, clinical trials should be considered as preferred treatment options for eligible patients (www.mdanderson.org/gynonctrials). Other co-morbidities are taken into consideration prior

More information

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most

More information

Cervical Cancer: 2018 FIGO Staging

Cervical Cancer: 2018 FIGO Staging Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford

More information

Indication for Surgery in Endometrial & Cervical Cancer. everything you need to know in 30 minutes!!! Fabio Landoni, MD Gynecologic Department

Indication for Surgery in Endometrial & Cervical Cancer. everything you need to know in 30 minutes!!! Fabio Landoni, MD Gynecologic Department Indication for Surgery in Endometrial & Cervical Cancer everything you need to know in 30 minutes!!! Fabio Landoni, MD Gynecologic Department Risk Factors LVSI Myometrial invasion Nodes grade Adjuvant

More information

VULVAR CARCINOMA. Page 1 of 5

VULVAR CARCINOMA. Page 1 of 5 VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node

More information

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix. Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying

More information

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review

More information

Role and Techniques of Surgery in Carcinoma Cervix. Dr Vanita Jain Additional Professor OBGYN PGIMER, Chandigarh

Role and Techniques of Surgery in Carcinoma Cervix. Dr Vanita Jain Additional Professor OBGYN PGIMER, Chandigarh Role and Techniques of Surgery in Carcinoma Cervix Dr Vanita Jain Additional Professor OBGYN PGIMER, Chandigarh Points for Discussion Pattern of spread Therapeutic options Types of surgical procedures

More information

Disclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose

Disclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017

More information

Neoplasia literally means "new growth.

Neoplasia literally means new growth. NEOPLASIA Neoplasia literally means "new growth. A neoplasm, defined as "an abnormal mass of tissue the growth of which exceeds and is uncoordinated with that of the normal tissues and persists in the

More information

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion 5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year

More information

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures

More information

Role of Surgery in Cervical Cancer & Research Questions

Role of Surgery in Cervical Cancer & Research Questions Role of Surgery in Cervical Cancer & Research Questions Arb-aroon Lertkhachonsuk, M.D., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Role of surgery in cervical cancer

More information

3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Breast Cancer. Pathologic Staging Updates Breast Cancer

3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Breast Cancer. Pathologic Staging Updates Breast Cancer Pathologic Staging Updates in Breast Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME

More information

UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE

UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE Case: Adenosarcoma with heterologous elements and stromal overgrowth o TAH, BSO, omentectomy, staging biopsies of cul-de-sac, bladder

More information

Stage IB1 (2-4 cm) Cervical cancer treated with Neoadjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA) Dre Marie Plante

Stage IB1 (2-4 cm) Cervical cancer treated with Neoadjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA) Dre Marie Plante Stage IB1 (2-4 cm) Cervical cancer treated with Neoadjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA) Dre Marie Plante Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical

More information

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas) C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2

More information

TOPICS FOR DISCUSSION

TOPICS FOR DISCUSSION INTERNATIONAL SOCIETY OF UROLOGIC PATHOLOGY PATHOLOGIC STAGING OF SELECT UROLOGIC MALIGNANCIES Mahul B. Amin, MD Professor and Chairman Pathology and Laboratory Medicine Cedars-Sinai Medical Center Los

More information

Gynecologic Cancers. What is Gynecologic Cancer. Who is at risk for GYN cancer? 3/1/2018 1

Gynecologic Cancers. What is Gynecologic Cancer. Who is at risk for GYN cancer? 3/1/2018 1 What is Gynecologic Cancer Gynecologic Cancers Marge Ramsdell RN, MN, OCN Madigan Army Medical Center Any cancer that starts in a woman s reproductive organs Each GYN cancer is unique 5 main types Cervical

More information

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas) CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR Last Revision Date July 2015 1 Site Group: Gynecologic Cancer Vulvar Author: Dr. Stephane Laframboise 1. INTRODUCTION

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND

More information

What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden

What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden Maastricht Pathology 2018 Wednesday 20 th June Endometrioid adenocarcinoma High grade carcinomas (common)

More information

International Society of Gynecological Pathologists Symposium 2007

International Society of Gynecological Pathologists Symposium 2007 International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade

More information

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients

More information

malignant polyp Daily Challenges in Digestive Endoscopy for Endoscopists and Endoscopy Nurses BSGIE Annual Meeting 18/09/2014 Mechelen

malignant polyp Daily Challenges in Digestive Endoscopy for Endoscopists and Endoscopy Nurses BSGIE Annual Meeting 18/09/2014 Mechelen Plan Incidental finding of a malignant polyp 1. What is a polyp malignant? 2. Role of the pathologist and the endoscopist 3. Quantitative and qualitative risk assessment 4. How to decide what to do? Hubert

More information

Staging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates

Staging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates Staging Challenges in Lower GI Cancers Sanjay Kakar, MD University of California, San Francisco March 05, 2017 Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education

More information

Controversies and Questions in the Surgical Treatment of Melanoma

Controversies and Questions in the Surgical Treatment of Melanoma Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School

More information

Update on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017

Update on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017 Update on staging colorectal carcinoma, the 8 th edition AJCC Dale C. Snover, MD November 3, 2017 General overview of staging Reason for uniform staging Requirements to use AJCC manual and/or CAP protocols

More information

A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008

A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator

More information

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates Signs

More information

Algorithms for management of Cervical cancer

Algorithms for management of Cervical cancer Algithms f management of Cervical cancer Algithms f management of cervical cancer are based on existing protocols and guidelines within the ESGO comunity and prepared by ESGO Educational Committe as a

More information

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health

More information

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%

More information

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given

More information

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

Management Algorithms for Abnormal Cervical Cytology and Colposcopy Management Algorithms for Abnormal Cervical Cytology and Colposcopy Table of Contents Standard Colposcopic Definitions... 1 Guidelines for the Assessment of Abnormal Cervical Cytology... 2 Ia: Persistent

More information

Tumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix

Tumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix Original Article J Gynecol Oncol Vol. 23, No. 3:153-158 pissn 2005-0380 eissn 2005-0399 Tumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix

More information

2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA

2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA 2009 USCAP Gyn Pathology Evening Session Case #3 Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA rzaino@psu.edu Clinical history Middle aged woman with an exophytic mass of

More information

Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University

Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University Cervical Cancer Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University Estimated gynecologic cancer cases United States

More information

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification

More information

Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage

Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage Jessica Johns, MD Jeffrey Killeen, MD Robert Kim, MD Hyeong Jun Ahn, PhD None Disclosures

More information

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April

More information

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)

More information

Cervical Cancer Guidelines L and SC Network July Introduction:

Cervical Cancer Guidelines L and SC Network July Introduction: Cervical Cancer Guidelines L and SC Network July 2018 Introduction: There was a total number of 442 cases of cervix cancer diagnosed in Lancashire and South Cumbria Cancer Network in the period 2005 2009

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased

Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts

More information

Janjira Petsuksiri, M.D

Janjira Petsuksiri, M.D GYN malignancies Janjira Petsuksiri, M.D Outlines Cervical cancer Endometrial cancer Ovarian cancer Vaginal cancer Vulva cancer 2 CA Cervix Epidemiology - Second most common female cancer Risk factors

More information

Clinical Pathological Conference. Malignant Melanoma of the Vulva

Clinical Pathological Conference. Malignant Melanoma of the Vulva Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge

More information

The Role of Radiation in the Management of Gynecologic Cancers. Scott Glaser, MD

The Role of Radiation in the Management of Gynecologic Cancers. Scott Glaser, MD The Role of Radiation in the Management of Gynecologic Cancers Scott Glaser, MD Nothing to disclose DISCLOSURE Outline The role of radiation in: Endometrial Cancer Adjuvant Medically inoperable Cervical

More information

GOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles

GOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to

More information

GOBLET CELL CARCINOID

GOBLET CELL CARCINOID GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to

More information

Rochester Minnesota Mayo Clinic

Rochester Minnesota Mayo Clinic Are There Still Indications for Lymphadenectomy in Endometrial Cancer? A Mariani Mayo Clinic Rochester - MN USA Rochester Minnesota Mayo Clinic 1 Endometrial Cancer Lymphadenectomy Yes or No? Endometrial

More information

3/27/2017. Pulmonary Pathology Specialty Conference. Disclosure of Relevant Financial Relationships. Clinical History:

3/27/2017. Pulmonary Pathology Specialty Conference. Disclosure of Relevant Financial Relationships. Clinical History: Pulmonary Pathology Specialty Conference Saul Suster, M.D. Medical College of Wisconsin Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position

More information

An Alphabet Soup of Thyroid Neoplasms

An Alphabet Soup of Thyroid Neoplasms Overall Objectives An Alphabet Soup of Thyroid Neoplasms Lester D. R. Thompson www.lester-thompson.com What is the current management of papillary carcinoma? What are the trends and what can we do differently?

More information

Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies. Agenda

Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies. Agenda Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University

More information

Gynaecological Pathology Reporting Cervical Pathology Dr Raji Ganesan Birmingham

Gynaecological Pathology Reporting Cervical Pathology Dr Raji Ganesan Birmingham Gynaecological Pathology Reporting Cervical Pathology Dr Raji Ganesan Birmingham Format Introduction Cervical biopsy Difficulties in diagnosis of CIN p16 Cervical loop Squamous carcinoma diagnosing and

More information

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings. Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year

More information

Vulva Cancer Histopathology Reporting Proforma

Vulva Cancer Histopathology Reporting Proforma Vulva Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Ethnicity Unknown AboriginalTorres

More information

Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center

Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center 50 yo healthy postmenopausal female with BMI = 35 with screening PAP smear = AGUS. What is the next step? (1) Colposcopy

More information

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior

More information

Definition of Synoptic Reporting

Definition of Synoptic Reporting Definition of Synoptic Reporting The CAP has developed this list of specific features that define synoptic reporting formatting: 1. All required cancer data from an applicable cancer protocol that are

More information

International prospective validation trial of sentinel node biopsy in cervical cancer

International prospective validation trial of sentinel node biopsy in cervical cancer Cervix cancer committee International prospective validation trial of sentinel node biopsy in cervical cancer N Abu-Rustum, F Lécuru, P Mathevet, M Plante. F Bonnetain (Statistics) G Chatellier (Clinical

More information

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with

More information

Ground Glass Opacities

Ground Glass Opacities Ground Glass Opacities A pathologist s perspective Marie-Christine Aubry, M.D. Professor of Pathology Mayo Clinic Objectives Discuss the proposed new pathologic classification of adenocarcinoma with historical

More information

ONCOLOGY. Csaba Bödör. Department of Pathology and Experimental Cancer Research november 19., ÁOK, III.

ONCOLOGY. Csaba Bödör. Department of Pathology and Experimental Cancer Research november 19., ÁOK, III. ONCOLOGY Csaba Bödör Department of Pathology and Experimental Cancer Research 2018. november 19., ÁOK, III. bodor.csaba1@med.semmelweis-univ.hu ONCOLOGY Characteristics of Benign and Malignant Neoplasms

More information

Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix?

Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? e-issn 1643-3750 DOI: 10.12659/MSM.897291 Received: 2015.12.27 Accepted: 2016.01.13 Published: 2016.02.08 Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? Authors Contribution:

More information

Possibility of less radical treatment for patients with early invasive uterine cervical cancer

Possibility of less radical treatment for patients with early invasive uterine cervical cancer doi:10.1111/jog.12980 J. Obstet. Gynaecol. Res. Vol. 42, No. 7: 876 882, July 2016 Possibility of less radical treatment for patients with early invasive uterine cervical cancer Miseon Kim, Shinichi Ishioka,

More information

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone

More information

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal Diseases of cervix I. Inflammations 1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal squamous mucosa

More information

The new FIGO classification in endometrial carcinoma

The new FIGO classification in endometrial carcinoma The new FIGO classification in endometrial carcinoma Poster No.: C-1073 Congress: ECR 2012 Type: Educational Exhibit Authors: A. IGLESIAS CASTAÑON, M. Arias Gonzales, J. Mañas Uxó, 1 2 1 2 2 2 B. NIETO

More information

Understanding Your Pap Test Results

Understanding Your Pap Test Results Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities

More information

Objectives. Intraoperative Consultation of the Whipple Resection Specimen. Pancreas Anatomy. Pancreatic ductal carcinoma 11/10/2014

Objectives. Intraoperative Consultation of the Whipple Resection Specimen. Pancreas Anatomy. Pancreatic ductal carcinoma 11/10/2014 Intraoperative Consultation of the Whipple Resection Specimen Pathology Update Faculty of Medicine, University of Toronto November 15, 2014 John W. Wong, MD, FRCPC Department of Anatomical Pathology Sunnybrook

More information

Intention-to-Treat Analysis of Radical Trachelectomy for Early-Stage Cervical Cancer With Special Reference to Oncologic Failures

Intention-to-Treat Analysis of Radical Trachelectomy for Early-Stage Cervical Cancer With Special Reference to Oncologic Failures ORIGINAL STUDY Intention-to-Treat Analysis of Radical Trachelectomy for Early-Stage Cervical Cancer With Special Reference to Oncologic Failures Single-Institutional Experience in Hungary Robert Póka,

More information

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic

More information

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates

More information

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml

More information

Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS

Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific

More information

WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?

WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19

More information

Cervical cancer presentation

Cervical cancer presentation Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000

More information

GLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016

GLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016 GLANDULAR LESIONS PITFALLS IN MANAGEMENT Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016 Introduction Cervical glandular lesions are much less common than squamous lesion Incidence

More information

Disclosure. Case. Mixed Tumors of the Uterine Corpus and Cervix. I have nothing to disclose

Disclosure. Case. Mixed Tumors of the Uterine Corpus and Cervix. I have nothing to disclose Mixed Tumors of the Uterine Corpus and Cervix Marisa R. Nucci, M.D. Division of Women s and Perinatal Pathology Department of Pathology Brigham and Women s Hospital Boston, MA UCSF Current Issues in Anatomic

More information

surgical staging g in early endometrial cancer

surgical staging g in early endometrial cancer Risk adapted d approach to surgical staging g in early endometrial cancer Leon Massuger University Medical Centre St Radboud Nijmegen, The Netherlands Doing nodes Yes Yes Yes No No No 1957---------------------------

More information

Evaluation of the Axilla Post Z-0011 Trial New Paradigm

Evaluation of the Axilla Post Z-0011 Trial New Paradigm Evaluation of the Axilla Post Z-0011 Trial New Paradigm Belinda Curpen, MD, FRCPC; Tetyana Dushenkovska; Mia Skarpathiotakis MD, FRCPC; Carrie Betel, MD, FRCPC; Kalesha Hack, MD, FRCPC; Lara Richmond,

More information

Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer

Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Its Not Just About the Nodes AACE Advances in Medical and Surgical Management of Thyroid Cancer - 2017 Robert A. Levine, MD,

More information